Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | CA1 | P00915 | 3/20 | 0.52 |
| ▸ | CA2 | P00918 | 3/20 | 0.52 |
| ▸ | CA7 | P43166 | 2/20 | 0.52 |
| ▸ | CA9 | Q16790 | 2/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA4 | P22748 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.45 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.43 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.43 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methyl Alcohol SCHEMBL27389806 | 0.91 | L3MBTL1 (0.59) | L3MBTL1TDP1CA1CA2CA7 | |
| SCHEMBL7027663 | 0.91 | — | — | |
| SCHEMBL29466747 | 0.91 | — | — | |
| SCHEMBL22390 | 0.91 | — | — | |
| Ammonia Solution, Strong SCHEMBL3209630 | 0.88 | L3MBTL1 (0.61) | L3MBTL1TDP1CA1CA2CA7 | |
| Water SCHEMBL27462263 | 0.88 | L3MBTL1 (0.61) | L3MBTL1TDP1CA1CA2CA7 | |
| Cyanide SCHEMBL27877009 | 0.84 | L3MBTL1 (0.57) | L3MBTL1TDP1CA1CA2CA7 | |
| Formaldehyde SCHEMBL29068682 | 0.84 | L3MBTL1 (0.57) | L3MBTL1TDP1CA1CA2CA7 | |
| 1,2-Dimethoxybenzene SCHEMBL1796149 | 0.83 | CA1 (0.77) | L3MBTL1TDP1CA1CA2CA7 | |
| 1,2-Dimethoxybenzene SCHEMBL23113 | 0.83 | CA1 (0.77) | L3MBTL1TDP1CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10301305-B2 | Heteroaromatic derivatives and their use as pharmaceuticals | MUTABILIS (FR) | 2019-05-28 | — | — | US | disclosed |
| EP-3110803-B1 | HETEROAROMATIC DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | MUTABILIS (FR) | 2018-07-11 | — | — | EP | disclosed |
| US-20170015661-A1 | HETEROAROMATIC DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | MUTABILIS (FR) | 2017-01-19 | — | — | US | disclosed |
| EP-3110803-A1 | HETEROAROMATIC DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | Mutabilis (FR) | 2017-01-04 | — | — | EP | disclosed |
| WO-2015128333-A1 | HETEROAROMATIC DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | LABORATOIRE BIODIM (FR) | 2015-09-03 | — | — | WO | disclosed |
| EP-2913330-A1 | Condensed derivatives of imidazole useful as pharmaceuticals | LABORATOIRE BIODIM (FR) | 2015-09-02 | — | — | EP | disclosed |
| EP-1809614-B1 | BENZOTRIAZINE INHIBITORS OF KINASES | TARGEGEN INC (US) | 2014-05-07 | — | — | EP | disclosed |
| EP-2609089-A1 | SELECTIVE 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | Universität des Saarlandes (DE) | 2013-07-03 | — | — | EP | disclosed |
| EP-2543376-A1 | Benzotriazine inhibitors of kinases | Targegen, Inc. (US) | 2013-01-09 | — | — | EP | disclosed |
| WO-2012025638-A1 | SELECTIVE 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | Universität des Saarlandes (DE) | 2012-03-01 | — | — | WO | disclosed |
| EP-1673355-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | Pfizer Limited (GB) | 2006-06-28 | — | — | EP | disclosed |
| CN-1738788-A | Substituted phenylnaphthalenes as estrogenic agents | WYETH CORP (US) | 2006-02-22 | — | — | CN | disclosed |
| US-20050245524-A1 | Benzotriazine inhibitors of kinases | TARGEGEN, INC. (US) | 2005-11-03 | — | — | US | disclosed |
| WO-2005096784-A2 | BENZOTRIAZINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2005-10-20 | — | — | WO | disclosed |
| WO-2005028452-A9 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | PFIZER LTD (GB) | 2005-07-21 | — | — | WO | disclosed |
| US-20050107382-A1 | e.g. 2-(4-fluoro-2-methylphenyl)-5-(5-methoxymethyl-4-(6-methoxypyridin-3-yl)-4H-[1,2,4]triazol-3-yl)-pyridine; treatment of arousal disorder, orgasmic disorder, sexual pain disorder and premature ejaculation, preterm labor, appetite and feeding disorders, dysmenorrhoea, congestive heart failure, etc. | PFIZER INC. | 2005-05-19 | — | — | US | disclosed |
| WO-2005028452-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | PFIZER LIMITED (GB) | 2005-03-31 | — | — | WO | disclosed |
| EP-0637624-B1 | Antiferroelectric liquid crystal compound | SHOWA SHELL SEKIYU (JP) | 1996-09-25 | — | — | EP | disclosed |
| US-5417885-A | Antiferroelectric liquid crystal compound | SHOWA SHELL SEKIYU KABUSHIKI KAISHA (JP) | 1995-05-23 | — | — | US | disclosed |
| EP-0637624-A1 | Antiferroelectric liquid crystal compound | Showa Shell Sekiyu Kabushiki Kaisha (JP) | 1995-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107382-A1 | e.g. 2-(4-fluoro-2-methylphenyl)-5-(5-methoxymethyl-4-(6-methoxypyridin-3-yl)-4H-[1,2,4]triazol-3-yl)-pyridine; treatment of arousal disorder, orgasmic disorder, sexual pain disorder and premature ejaculation, preterm labor, appetite and feeding disorders, dysmenorrhoea, congestive heart failure, etc. | OXTR, OPRL1, NPY4R | L3MBTL1 2050/4885TDP1 1444/4885CA1 4798/4885 |
| US-20050245524-A1 | Benzotriazine inhibitors of kinases | SRC, CAMK4, CAMK2G | L3MBTL1 4654/4885TDP1 1492/4885CA1 3214/4885 |
| US-20170015661-A1 | HETEROAROMATIC DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | MSR1, IFNAR1, NOD2 | L3MBTL1 2541/4885TDP1 4609/4885CA1 4017/4885 |
| US-10301305-B2 | Heteroaromatic derivatives and their use as pharmaceuticals | MSR1, IFNAR1, NOD2 | L3MBTL1 2541/4885TDP1 4609/4885CA1 4017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.